Phenotypes Associated with This Genotype

Genotype
MGI:4414761

• Allelic Composition: Paqr3^tm1Ychn/Paqr3^tm1Ychn
• Genetic Background: involves: 129 * C57BL/6J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased incidence of tumors by chemical induction ( J:139058 )

• markedly increased proliferation of keratinocytes in response to DMBA (7, 12-dimethylbenz(a) anthracene) and TPA (12-O-tetradecanoylphorbol-13-acetate)

• apoptosis is markedly reduced in DMBA and TPA induced tumors in comparison with the tumors from wild-type mice

• papillomas begin to appear at 11 weeks post DMBA and TPA treatment compared to 15 weeks in wild-type mice

• at 20 weeks after DMAB and TPA treatment about 80% of mice have papillomas compared to 40% of wild-type mice

increased skin papilloma incidence ( J:139058 )

• the number of DMBA and TPA induced papillomas per mouse is markedly increased

increased tumor growth/size ( J:139058 )

• the average number of large DMAB and TPA induced tumors (.5 mm in diameter) is profoundly increased at 20 weeks after DMBA and TPA treatment most tumors are still growing, unlike in wild-type mice where tumors are beginning to undergo growth arrest and dessication

increased carcinoma incidence ( J:139058 )

• at 20 weeks after DMBA and TPA treatment some papillomas have progressed to malignant carcinomas, no such progression is detected in wild-type mice

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:139058 )

• markedly increased proliferation of keratinocytes in response to DMBA (7, 12-dimethylbenz(a) anthracene) and TPA (12-O-tetradecanoylphorbol-13-acetate)

• apoptosis is markedly reduced in DMBA and TPA induced tumors in comparison with the tumors from wild-type mice

• papillomas begin to appear at 11 weeks post DMBA and TPA treatment compared to 15 weeks in wild-type mice

• at 20 weeks after DMAB and TPA treatment about 80% of mice have papillomas compared to 40% of wild-type mice

integument

increased keratinocyte proliferation ( J:139058 )

• markedly increased proliferation of keratinocytes in response to DMBA (7, 12-dimethylbenz(a) anthracene) and TPA (12-Otetradecanoylphorbol-13-acetate) treatment

thick epidermis ( J:139058 )

• average thickness of the epidermis is significantly increased in response to DMBA (7, 12-dimethylbenz(a) anthracene) and TPA (12-O-tetradecanoylphorbol-13-acetate), unlike in wild-type mice

increased skin papilloma incidence ( J:139058 )

• the number of DMBA and TPA induced papillomas per mouse is markedly increased

cellular

increased keratinocyte proliferation ( J:139058 )

• markedly increased proliferation of keratinocytes in response to DMBA (7, 12-dimethylbenz(a) anthracene) and TPA (12-Otetradecanoylphorbol-13-acetate) treatment